Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2026)

Aquestive Therapeutics' Cash from Operations history runs 10 years deep, the most recent figure standing at 14806000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 36.73% year-over-year to 14806000.0; the TTM figure through Mar 2026 stood at 43838000.0 (up 10.12% YoY), while the FY2025 annual figure was 52432000.0, down 46.63% from the prior year.
• Cash from Operations was 14806000.0 for Q1 2026 at Aquestive Therapeutics, down from 8469000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 8816000.0 in Q1 2023 to a low of 23400000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 7011529.41 across 5 years, with a median of 7907000.0 in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 204.4% in 2022, then slumped 406.18% in 2024.
• A 5-year view of Cash from Operations shows it stood at 8416000.0 in 2022, then sank by 158.72% to 4942000.0 in 2023, then slumped by 31.3% to 6489000.0 in 2024, then sank by 30.51% to 8469000.0 in 2025, then tumbled by 74.83% to 14806000.0 in 2026.
• The last three Cash from Operations figures came in at 14806000.0 (Q1 2026), 8469000.0 (Q4 2025), and 12649000.0 (Q3 2025), per Business Quant data.